Cargando…

MiR-4763-3p targeting RASD2as a Potential Biomarker and Therapeutic Target for Schizophrenia

Existing diagnostic methods are limited to observing appearance and demeanor, even though genetic factors play important roles in the pathology of schizophrenia. Indeed, no molecular-level test exists to assist diagnosis, which has limited treatment strategies. To address this serious shortcoming, w...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jiao, Qi, Wenxin, Shi, Hongwei, Huang, Lin, Ning, Fujiang, Wang, Fushuai, Wang, Kai, Bai, Haotian, Wu, Hao, Zhuang, Junyi, Hong, Huanle, Zhou, Haicong, Feng, Hu, Zhou, Yinping, Dong, Naijun, Liu, Li, Kong, Yanyan, Xie, Jiang, Zhao, Robert Chunhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JKL International LLC 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9286908/
https://www.ncbi.nlm.nih.gov/pubmed/35855328
http://dx.doi.org/10.14336/AD.2022.0103
_version_ 1784748126429511680
author Wang, Jiao
Qi, Wenxin
Shi, Hongwei
Huang, Lin
Ning, Fujiang
Wang, Fushuai
Wang, Kai
Bai, Haotian
Wu, Hao
Zhuang, Junyi
Hong, Huanle
Zhou, Haicong
Feng, Hu
Zhou, Yinping
Dong, Naijun
Liu, Li
Kong, Yanyan
Xie, Jiang
Zhao, Robert Chunhua
author_facet Wang, Jiao
Qi, Wenxin
Shi, Hongwei
Huang, Lin
Ning, Fujiang
Wang, Fushuai
Wang, Kai
Bai, Haotian
Wu, Hao
Zhuang, Junyi
Hong, Huanle
Zhou, Haicong
Feng, Hu
Zhou, Yinping
Dong, Naijun
Liu, Li
Kong, Yanyan
Xie, Jiang
Zhao, Robert Chunhua
author_sort Wang, Jiao
collection PubMed
description Existing diagnostic methods are limited to observing appearance and demeanor, even though genetic factors play important roles in the pathology of schizophrenia. Indeed, no molecular-level test exists to assist diagnosis, which has limited treatment strategies. To address this serious shortcoming, we used a bioinformatics approach to identify 61 genes that are differentially expressed in schizophrenia patients compared with healthy controls. In particular, competing endogenous RNA network revealed the important role of the gene RASD2, which is regulated by miR-4763-3p. Indeed, analysis of blood samples confirmed that RASD2 is downregulated in schizophrenia patients. Moreover, positron emission tomography data collected for 44 human samples identified the prefrontal and temporal lobes as potential key brain regions in schizophrenia patients. Mechanistic studies indicated that miR-4763-3p inhibits RASD2 by base-pairing with the 3’ untranslated region of RASD2 mRNA. Importantly, RASD2 has been shown to interact with β-arrestin2, which contributes to the regulation of the DRD2-dependent CREB response element-binding protein pathway in the dopamine system. Finally, results obtained with a mouse model of schizophrenia revealed that inhibition of miR-4763-3p function alleviated anxiety symptoms and improved memory. The dopamine transporters in the striatal regions were significantly reduced in schizophrenia model mice as compared with wild-type mice, suggesting that inhibition of miR-4763-3p can lessen the symptoms of schizophrenia. Our findings demonstrate that miR-4763-3p may target RASD2 mRNA and thus may serve as a potential biomarker and therapeutic target for schizophrenia, providing a theoretical foundation for further studies of the molecular basis of this disease.
format Online
Article
Text
id pubmed-9286908
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher JKL International LLC
record_format MEDLINE/PubMed
spelling pubmed-92869082022-07-18 MiR-4763-3p targeting RASD2as a Potential Biomarker and Therapeutic Target for Schizophrenia Wang, Jiao Qi, Wenxin Shi, Hongwei Huang, Lin Ning, Fujiang Wang, Fushuai Wang, Kai Bai, Haotian Wu, Hao Zhuang, Junyi Hong, Huanle Zhou, Haicong Feng, Hu Zhou, Yinping Dong, Naijun Liu, Li Kong, Yanyan Xie, Jiang Zhao, Robert Chunhua Aging Dis Original Article Existing diagnostic methods are limited to observing appearance and demeanor, even though genetic factors play important roles in the pathology of schizophrenia. Indeed, no molecular-level test exists to assist diagnosis, which has limited treatment strategies. To address this serious shortcoming, we used a bioinformatics approach to identify 61 genes that are differentially expressed in schizophrenia patients compared with healthy controls. In particular, competing endogenous RNA network revealed the important role of the gene RASD2, which is regulated by miR-4763-3p. Indeed, analysis of blood samples confirmed that RASD2 is downregulated in schizophrenia patients. Moreover, positron emission tomography data collected for 44 human samples identified the prefrontal and temporal lobes as potential key brain regions in schizophrenia patients. Mechanistic studies indicated that miR-4763-3p inhibits RASD2 by base-pairing with the 3’ untranslated region of RASD2 mRNA. Importantly, RASD2 has been shown to interact with β-arrestin2, which contributes to the regulation of the DRD2-dependent CREB response element-binding protein pathway in the dopamine system. Finally, results obtained with a mouse model of schizophrenia revealed that inhibition of miR-4763-3p function alleviated anxiety symptoms and improved memory. The dopamine transporters in the striatal regions were significantly reduced in schizophrenia model mice as compared with wild-type mice, suggesting that inhibition of miR-4763-3p can lessen the symptoms of schizophrenia. Our findings demonstrate that miR-4763-3p may target RASD2 mRNA and thus may serve as a potential biomarker and therapeutic target for schizophrenia, providing a theoretical foundation for further studies of the molecular basis of this disease. JKL International LLC 2022-07-11 /pmc/articles/PMC9286908/ /pubmed/35855328 http://dx.doi.org/10.14336/AD.2022.0103 Text en copyright: © 2022 Wang et al. https://creativecommons.org/licenses/by/2.0/this is an open access article distributed under the terms of the creative commons attribution license, which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.
spellingShingle Original Article
Wang, Jiao
Qi, Wenxin
Shi, Hongwei
Huang, Lin
Ning, Fujiang
Wang, Fushuai
Wang, Kai
Bai, Haotian
Wu, Hao
Zhuang, Junyi
Hong, Huanle
Zhou, Haicong
Feng, Hu
Zhou, Yinping
Dong, Naijun
Liu, Li
Kong, Yanyan
Xie, Jiang
Zhao, Robert Chunhua
MiR-4763-3p targeting RASD2as a Potential Biomarker and Therapeutic Target for Schizophrenia
title MiR-4763-3p targeting RASD2as a Potential Biomarker and Therapeutic Target for Schizophrenia
title_full MiR-4763-3p targeting RASD2as a Potential Biomarker and Therapeutic Target for Schizophrenia
title_fullStr MiR-4763-3p targeting RASD2as a Potential Biomarker and Therapeutic Target for Schizophrenia
title_full_unstemmed MiR-4763-3p targeting RASD2as a Potential Biomarker and Therapeutic Target for Schizophrenia
title_short MiR-4763-3p targeting RASD2as a Potential Biomarker and Therapeutic Target for Schizophrenia
title_sort mir-4763-3p targeting rasd2as a potential biomarker and therapeutic target for schizophrenia
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9286908/
https://www.ncbi.nlm.nih.gov/pubmed/35855328
http://dx.doi.org/10.14336/AD.2022.0103
work_keys_str_mv AT wangjiao mir47633ptargetingrasd2asapotentialbiomarkerandtherapeutictargetforschizophrenia
AT qiwenxin mir47633ptargetingrasd2asapotentialbiomarkerandtherapeutictargetforschizophrenia
AT shihongwei mir47633ptargetingrasd2asapotentialbiomarkerandtherapeutictargetforschizophrenia
AT huanglin mir47633ptargetingrasd2asapotentialbiomarkerandtherapeutictargetforschizophrenia
AT ningfujiang mir47633ptargetingrasd2asapotentialbiomarkerandtherapeutictargetforschizophrenia
AT wangfushuai mir47633ptargetingrasd2asapotentialbiomarkerandtherapeutictargetforschizophrenia
AT wangkai mir47633ptargetingrasd2asapotentialbiomarkerandtherapeutictargetforschizophrenia
AT baihaotian mir47633ptargetingrasd2asapotentialbiomarkerandtherapeutictargetforschizophrenia
AT wuhao mir47633ptargetingrasd2asapotentialbiomarkerandtherapeutictargetforschizophrenia
AT zhuangjunyi mir47633ptargetingrasd2asapotentialbiomarkerandtherapeutictargetforschizophrenia
AT honghuanle mir47633ptargetingrasd2asapotentialbiomarkerandtherapeutictargetforschizophrenia
AT zhouhaicong mir47633ptargetingrasd2asapotentialbiomarkerandtherapeutictargetforschizophrenia
AT fenghu mir47633ptargetingrasd2asapotentialbiomarkerandtherapeutictargetforschizophrenia
AT zhouyinping mir47633ptargetingrasd2asapotentialbiomarkerandtherapeutictargetforschizophrenia
AT dongnaijun mir47633ptargetingrasd2asapotentialbiomarkerandtherapeutictargetforschizophrenia
AT liuli mir47633ptargetingrasd2asapotentialbiomarkerandtherapeutictargetforschizophrenia
AT kongyanyan mir47633ptargetingrasd2asapotentialbiomarkerandtherapeutictargetforschizophrenia
AT xiejiang mir47633ptargetingrasd2asapotentialbiomarkerandtherapeutictargetforschizophrenia
AT zhaorobertchunhua mir47633ptargetingrasd2asapotentialbiomarkerandtherapeutictargetforschizophrenia